Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA and reacts with SARS-CoV-2, SARS-CoV samples.
pH: 7.4
Preservative: 0.02% Proclin 300
Constituents: 99.9% PBS
| ELISA | |
|---|---|
| SARS-CoV | Expected |
| SARS-CoV-2 | Expected |
| Species | Dilution info | Notes |
|---|---|---|
Species SARS-CoV-2, SARS-CoV | Dilution info Use at an assay dependent concentration. | Notes - |
Spike glycoprotein. May down-regulate host tetherin (BST2) by lysosomal degradation, thereby counteracting its antiviral activity. Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection (By similarity). Binding to human ACE2 and CLEC4M/DC-SIGNR receptors and internalization of the virus into the endosomes of the host cell induces conformational changes in the S glycoprotein. Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membrane fusion within endosomes. Spike protein S2. Mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Spike protein S2'. Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis.
S
2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein
Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA and reacts with SARS-CoV-2, SARS-CoV samples.
pH: 7.4
Preservative: 0.02% Proclin 300
Constituents: 99.9% PBS
This product is manufactured by BioVision, an Abcam company and was previously called A2103 Anti-CoV-2 & SARS-CoV S1 Antibody (Clone CR3022). A2103-200 is the same size as the 200 μg size of ab286179.
The SARS spike glycoprotein also known as the COVID-19 spike protein is an important target in the study of coronaviruses. This protein with a mass of approximately 180–200 kDa plays an essential role in the virus's ability to infect host cells. Expressed on the surface of the virus the spike protein facilitates the viral entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptors present on human cells. Through this interaction the spike protein initiates the fusion of the viral membrane with the host cell membrane enabling the virus to infiltrate the host.
The spike protein performs several significant functions beyond its role in viral entry. It forms part of a larger viral structure together with other proteins that maintain the virus's shape and functionality. The spike protein is integral in host immune system activation as it contains multiple antigenic sites that elicit an immune response. These antigenic sites become targets for antibodies that neutralize the virus. Researchers often focus on this aspect to develop vaccines and therapeutic interventions as it determines the body's capacity to fight off the infection.
The spike protein impacts both viral lifecycle and immune response pathways. During the viral lifecycle it is critical for initiating receptor-mediated endocytosis a pathway by which the virus gains cellular entry. Additionally its interaction with ACE2 links it to the renin-angiotensin system (RAS) pathway impacting cardiovascular regulation. Proteins such as TMPRSS2 which assists in priming the spike protein for membrane fusion also play a significant role within these pathways. Understanding these mechanisms contributes to the development of strategies to inhibit virus action and spread.
The spike protein is closely associated with COVID-19 the disease caused by the SARS-CoV-2 virus. Its function directly relates to the virus's ability to cause acute respiratory distress syndrome (ARDS) a severe condition common in critical COVID-19 patients. Researchers also study its potential links to cardiovascular issues as seen with co-expression and interaction with ACE2 in heart tissue. Furthermore the immune response triggered by the spike protein leads to the production of anti-spike protein antibodies which are vital components of serological tests for COVID-19 diagnostics and monitoring.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com